PCU Manual Phar and Cosumer Protection

8/12/2019 PCU Manual Phar and Cosumer Protection

1/156


2/156

9,750

2554


3/156


4/156

2 17 1.

1) 2)

. . 3) . . 4) . . 5)

6) 7) . . 8)

. . 9) 2. 1)

2) 3) . . 4) . . 5)

6) . . 7) :

8)


5/156

1 1 1 1 1 () () () () ()1. 1. 1. 1. 1. 1.1 1.2 1.3 2. (Empowerment)2. (Empowerment)2. (Empowerment)2. (Empowerment)2. (Empowerment)2.1 2.2 3. (Risk management)3. (Risk management)3. (Risk management)3. (Risk management)3. (Risk management)3.1 (Risk assessment)3.2 (Risk management)3.3 (Risk Communication) 1. 2. ( .)

3. 4.

2 2 2 2 2

-

713

131414171718212223262929

3134

36

4159

85


6/156

1 : 2 :

3 :

4 :

5 :

6 :

7 :

8 : ( ) 9 : ( ) 10 : ( ) 11 : ( )

12 : ( )

/ 13 : ( )

(Empowerment ) 14 : 15 :

16 : 17 :


7/156

()


8/156

2


9/156

3

(demand)

( )


10/156

4

( . .)

( .)

5

1. 2. 3. 4. 5.


11/156

5

3 . ( - -

) " "

" "

" "

1. 2. (Empowerment)3. (Risk

management)


12/156

6

.

. .

( E m p o w e r m e n t )

( R i s k m a n a g e m e n t )


13/156

1.


14/156

8


15/156

9

3

1.

1.2. 3.

1.2.

1.11.11.11.11.1 1.1.1

-


16/156

10

- . .

-

1.1.2

1.1.3

1.21.21.21.21.21.2.1

1.2.2 (Base line data)

1.3 1.3 1.3 1.3 1.3 1.3.1

1.3.2


17/156

11

2.


18/156

12


19/156

13

2

2.12.12.12.12.1 2.1.1

2. ( Empo we rme n t )


20/156

14

( ) ( )

2.1.2

2.1.3

2.2 2.2 2.2 2.2 2.2


21/156

3. (Risk management)


22/156

16


23/156

17

Model Risk Management Model

Model ( Model )

3.

( Ris k ma nageme n t )


24/156


25/156

19

3.1.2 (Exposure assessment) ( 3.1.1)

3.1.3 (Risk characterization)

( 3.1.13.1.2)

3.2 (Risk Management)3.2 (Risk Management)3.2 (Risk Management)3.2 (Risk Management)3.2 (Risk Management)

3.1.1 ,3.1.2 3.1.3

3.2.1 (Risk minimization)


26/156

20

(

)

/ / / / /


27/156

21

3.2.2

3.2.3 (Risk monitoring

and review)

3.2.4 (Policy)


28/156

22

3.3 (Risk Communication)3.3 (Risk Communication)3.3 (Risk Communication)3.3 (Risk Communication)3.3 (Risk Communication)

,

1.

1.1 1.2 1.3

2. 2.1 /

2.2

3.

3.1 3.2


29/156


30/156

24


31/156

25

1.


32/156

26

.

3 . ( - - )

" " " "

" "


33/156

27

. .

. .

(Best Practice)

( .)

2.

( . )


34/156

28

. . 2546-2548 . ( .)

. . 2549 . " . .

2549-2551" " ( .)"

. . 2552 . . 2

1.

2.

3.

4.

3 1


35/156

29

2

3

.

.

( . .) .

. . -

( )-

( .)


36/156

30

- .

-

- (

)

( .) .

" "

3.


37/156

31

" "

2553 .

(

150,000 200 ) 2554

2553


38/156

32

"

"

4.


39/156

33

(

) ( .) ( )

30

( )


40/156

34

( .)

.


41/156

5


42/156

36


43/156

37

( . .)

" "

1. " "

2. " " . .

. .

1. :


44/156

38

. .

3. " " . .

( )4. " "

(Compliance)

(Inappropriate Prescribing)


45/156

39

"

. . "

: ( )

( )

:

:

2.


46/156

40

(Fee for Services)

3. - ( ) -

:


47/156

41

1.1.1.1.1. - - - - -

- Flunarizine, Kaolin pectin Erythromycin estolate ( http://www.haiap.org/objectives/rum/project-banned-drugs/)

- NOXY oxytetracycline NOXZY

Loperamide-


48/156

42

- Serratiopeptidase (

Dasen? Danzen? )

1

- - - - -

1.

. . 2510

2.

1Takeda Voluntarily Recalls its Anti-inflammatory Enzyme Preparation, Dasen? in Japan. (21 Feb

2011) http://www.takeda.com/press/article_40162.html


49/156

43

2 2551 http://www.thaifda.com/ed2547/?pg=result

3 . . .

2542. http://203.157.213.9/fda/system/system2.htm

16

10-24 2

3.

3

(Good health at low cost)

- 750

550 350


50/156

44

-

70:30

80:20 90:10

4.

( .).

4 Phenopthalein kaolin

pectin amoxicillin

2. - 2. - 2. - 2. - 2. - 1.

. . 2552 ( .)

960 94.14 5.86

(


51/156

45

- 2552

10

. )

2. antidote

3.

- - - - - 1.

" Good manufacturing

Practices, GMP" GMP

2.


52/156

46

3. (CL) . . 2549

7

4.

.

3.3.3.3.3. - - - - -

. .

(Cold Chain) . 2552

9.9 90


53/156

47

- - - - -

Vendor ManagementInventory (VMI)

4. - 4. - 4. - 4. - 4. -

Superbug


54/156

48

E. Coli. - - - - -

(Clinical Practice Guidelines)

.


55/156

49

4.

14 2554

.

(Pay for Peformance)


56/156

50

/


57/156

51


58/156

52

1. .

2552. .: . 2553.

2. . . .

. . - .


59/156

6


60/156

54


61/156

55

1.

2. 3.

4.

- (Selection of drug)- (Procurement)- (Distribution)- (Utilization)


62/156

56

( .)

" "

.

. .

. .


63/156

57

( .) .

----- .

1. 2. 3. 4.

. 1 01, 5.

6.

7. ()


64/156

58

8.

1. -

.

.

.

( ) . .


65/156

59

.

. .

.

1.

2.

3.

2.


66/156

60

4.

5. .

1.

2.

3.

4.


67/156

61

1.

1.1 3 .301(

.)1.2 1.3

1.4 1.5

1.1 - 1.4

2 -

1. .

2. .


68/156

62

1.

2.

.

2.

2.1 1 .301

(stock 0

) ( . 301 16.1)2.2

2.3 2.4

(

16.2)


69/156

63

2.5 2.6 2.4,2.5

( )

2.7 2.8

2.1 -2.7

1.

2. 3.

4.

5.


70/156

64

1.

2.

( 16.3)

3.

1. 2.


71/156


72/156

66

2. : .

3. . 1 01 : , , ,

( )

. ( ) . 1 01

4. .301 :

.

5. / .: /

, , , , , , ,

6.


73/156


74/156

68

: .

1.2

.

1.2.1 1. .301 :

2. :

3. . : 2( 1 1 ) ,

, ( + 1 2 )

4. (

16.4)1.2.2 .


75/156

69

1. .

2. .

3. -4.

,

.

: : : : :1. .

.301

/

2.

3. /


76/156

70

" "

4. .

5. . . / /

'

, ' , ' Stock card .301

6. . .

4.1 . 4.2 .

4

. 1 01 ,


77/156

71

.1 01 3.

1.1.1 . 3 .1 01

. 1. .2. 3. -

( )4. 5. 6. 7. 8. ( " ")

5. ( Expir ed dr ug) , ( Dead stock) , ( Over stock)

5.15.15.15.15.1


78/156

72

- 15 - 30

- 2-8

- Keep in Freezer - Cool Place - 5.25.25.25.25.2 - Pack

' , ' , '-

- 5- 3- 3- 3- 1

( Pre-pack) 1

1


79/156

73

- 8

-

.

5.35.35.35.35.3 (Dead stock) (Dead stock) (Dead stock) (Dead stock) (Dead stock)

1

.

5.45.45.45.45.4 (Over stock) (Over stock) (Over stock) (Over stock) (Over stock) Over stock


80/156

74

5.55.55.55.55.5

1 2

6.

1.

2. /


81/156

75

3. / / .4.

1.

2.

3. .

7. ( )

.

( ) . 2-8

( )

"


82/156

76

2554"

1. Stock

2.

15 .3. 4.

First expire in First expire out5. 56. Ice pack

7.

8. 2 - 89. 2

10.

11.


83/156

77

. .

.

.

8.


84/156

78

/

1

.

( 16.5)

( )

. 1-5 .


85/156


86/156

80


87/156

81

( .)

. .

.

(High Alert Drugs)

( )


88/156

82

. (

) (

.

) 1 2 / 3 3

4

.


89/156

83

1

1. - /OPD Card

2. 3.

4.

5.

, , , ,(DI) ,

6. -

(Medication error) - -

7.


90/156

84

1. / 2. / -

, , , , ( )

3.

1. 2. / / 13.

2 /

3

1. , - , , , , ,

, ( , )

4


91/156

85

5 2

2.

3.

5.1 Identified 5.1 Identified 5.1 Identified 5.1 Identified 5.1 Identified 1. 2. " / "

5.2 5.2 5.2 5.2 5.2 (Prime Questions) (Prime Questions) (Prime Questions) (Prime Questions) (Prime Questions)

- /- /- - /-

-

- Exit care

- /


92/156

86

(Drug Counselling)(Drug Counselling)(Drug Counselling)(Drug Counselling)(Drug Counselling)

1.

2. 3.

4. 5. 6. 3

...


93/156

87


94/156

88


95/156

89

. . 2522

1. 1. 1. 1. 1.

2. 2. 2. 2. 2.

3. 3. 3. 3. 3.

1 :


96/156

90

4. --4. --4. --4. --4. --

2

5. 5. 5. 5. 5.

. .2510

2 7

1. 2. 3. 4.

2 :


97/156

91

5. 6. 7.

1-6 1- 4

1 - 4 ,6 7

-

1.1.1.1.1. - (.1) - (.1) - (.1) - (.1) - (.1)

( )

( 21)

- ( 39)


98/156

92

(

)

2.2.2.2.2. - - - - - (.2) (.2) (.2) (.2) (.2)

(

)3.3.3.3.3. - - - - -

4.4.4.4.4. - - - - -

( )5.5.5.5.5. - (.) - (.) - (.) - (.) - (.)

(

)

3 4 3

1. 32. 3 4


99/156

93

( )

1. 2.

, . 2 ,

3 4 , - ,

3. 4.

5.

-


100/156

94

-- .. 2522-- .. 2522-- .. 2522-- .. 2522-- .. 2522 . .2522

----------

4

1. , , , , ,

2. ( )

, , , ,

3 :


101/156

95

3. , ,

, , ,

4. 3 , , ,

-- -- -- -- -- 25

1.1.1.1.1. - -

-

- -

2.2.2.2.2. -


102/156

96

-

-

-

-

( 30

)3.3.3.3.3. - 4.4.4.4.4.

40 40 40 40 40

41 41 41 41 41


103/156

97

4 :

-- ..2535-- ..2535-- ..2535-- ..2535-- ..2535 . . 2535


104/156

98

" ."

""

1. -

( )


105/156

99

2.

3.

1.1.1.1.1. (Irritation)


106/156

100

2.2.2.2.2. (Allergy)

1.

2.

3.

4.


107/156

101

5.

6. 7.

8. (AHAs ,Alpha

Hydroxy Acids)

24-48


108/156

102

1.

2.

( )

3. 4.

5. 6.

7. 8.


109/156

103

1. , , ,

2. , , ,

, ,

5 :

- -

-

-


110/156

104

1.

- 40 . 120 .

- 10 .-

5 .-

-

- 12345678901 - 12345678901 - 12345678901 - 12345678901 - 12345678901

1. / 2. / 3. 4. 5. 6. 7. 8.


111/156

105

2.

3.

4. 5.

6. 7.

-

. . 2541

- 31 59 10,000


112/156

106

-

-

- /

-

32(1)

32(2)

32(3)

35(1)

59

59

59

65

10,000

10,000

10,000

20,000


113/156

107

" " . .2542

; , ,

. .2522

1. . .2510 2. . .25223. . .2551

3 1. . .25352. . .2535

6 :


114/156

108

2

1. . .2522

2. . .2518

2

1. . .2533

( )

2. . .2541 (

)3. . .25224. (

)


115/156

109

1. 1. 1. 1. 1.

100%

2. 2. 2. 2. 2.

7 :


116/156

110

3. ( )3. ( )3. ( )3. ( )3. ( )

MFG ......... (Manufacturing date) , EXP ......... (Expiry date)

2 39 , 2/1/39 ,2 JAN 96

4. 4. 4. 4. 4.

, , ,

5. -5. -5. -5. -5. -

( 5 . .......)


117/156

111

6. 6. 6. 6. 6.

- . (

.)

- - , , , ( ) , ,


118/156

112

8 : ( )

( ) / /


119/156

113

9 : ( )

..................................................................


120/156


121/156

115

11 : ( )


122/156

116

12 : ( )

/


123/156

117

13 : ( ) ( E mpowe r me nt )


124/156

118

14 :

1. ( , ., . )

2.

3. BIO DIESEL4. BIO DIESELGLYCERIN 5. DVD BIO DIESEL6. DVD BIO DIESEL7. -8. DVD -9. DVD 10. 11. , ,

12.

13. 8

14.


125/156

119

" "

3

1. 1. 1. 1. 1.

(Generic name)

15 :


126/156

120

( . . . 2510)

( )

( . )

( Lot No.

) (Mfg Date Mfd.) ( Expiry Date

Exp. Date)


127/156

121

2 . .

17 (

10- 25 )


128/156


129/156


130/156

124

.

2. 2. 2. 2. 2.


131/156

125

/

/

1-2

(NSAIDs)


132/156

126

1) 2)

3)

4)

1)


133/156

127

2)

3)

4)

3. 3. 3. 3. 3.

-

3.13.13.13.13.1


134/156

128

Reye's syndrome

1 2550

1.

18 2.

3. 4. 5. 6.


135/156

129

3.2 (Antidiarrhoeal combin3.2 (Antidiarrhoeal combin3.2 (Antidiarrhoeal combin3.2 (Antidiarrhoeal combin3.2 (Antidiarrhoeal combin

- 2552

1. Diiodohydroxyquinoline (

, )

Optic atrophy

2. Furazolidone (50 mg) (Anemia)


136/156

130

1 Glucose-6-phosphatedehydrogenase deficiency (G6PD) Furazolidone

3. Neomycin sulfate (50 mg equivalent to Neomycinbase 35 mg) (Ototoxicity)

, , (Nephrotoxicity) (Malabsorption syndrome)

4. Phthalylsulfathiazole (250 mg)

Pseudomembranous colitis Kernicterus Toxic epidermal necrolysis Stevens-

Johnson syndrome Anaphylaxis

5. Light kaolin (250 mg) ( ,, ,

)


137/156

131

3.3 3.3 3.3 3.3 3.3

2552

" " ( )

1. Methylene blue


138/156

132

2. Potassium nitrate (methaemoglobinemia)

(carcinogenicity)3. Hexamine

(hematuria) formaldehyde

4. 4. 4. 4. 4. : : : : :

4.14.14.14.14.1 ............... : : : : : ( 80)


139/156

133

.....

.....

/

( ) (

7-14 )

( ) (

)


140/156

134

4.2 ...?4.2 ...?4.2 ...?4.2 ...?4.2 ...? 2550

1,433,230 1.3

38

/

( 99%)


141/156

135

4.3 ?4.3 ?4.3 ?4.3 ?4.3 ?

6

1. (1. 2.

3. 4.

5. )

2.

penicillin Co-amoxiclav, cephalosporins cloxacillin


142/156

136

-

( )

5. 5. 5. 5. 5.


143/156

137

www.thaidrugwatch.org 02-2188452

1.

. " " " " " " 28 . . 54 : http://www.kapookya.com

2. . ...

28 . . 54 : http://www.oryor.com/oryor/admin/module/fda_pub_leaflet/file/f_5_1252308200.pdf

3.

4 .11/2552 25 2552

4. Antibiotics Smart Use.

28 . . 54 : http://newsser.fda.

moph.go.th/rumthai/asu/download.php


144/156

138

16.1 . 30116.2

16.3 16.4 ( )

......16.5

14 :


145/156

139

1 6 . 1

. 3

0 1


146/156


147/156

141

2552, 2553 . .

()()()()()

( Visit) ( Visit) ( Visit) ( Visit) ( Visit)

25522553

53= (18914 - 17823) x 100 = 6.1% 17823

53= (397562 - 350423) x 100 = 13.4% 350423

17,82318,914

350,423397,562


148/156

142

1 6 . 3


149/156

143


150/156


151/156

145

1 6 . 5


152/156


153/156

147

9. ( )

1 .253210.

( ) . .253311.

( ) 253512.

( ,

) . .255313. 2552

2553(

)14. (

)

4 12 downlohttp://www.thaihealthconsumer.orghttp://www.thaihealthconsumer.orghttp://www.thaihealthconsumer.orghttp://www.thaihealthconsumer.orghttp://www.thaihealthconsumer.org 13-14 download www.thaidrugwatch.orgwww.thaidrugwatch.orgwww.thaidrugwatch.orgwww.thaidrugwatch.orgwww.thaidrugwatch.org


154/156

148

2321/2533

/

2553

1. .

2. .

3. .

4. .


155/156

149

5. .

6. .

7. . . .

8. . .

9. .

10. .

11. .

12. .

13. .


156/156

14. . .

1.

2.

3. 4.

PCU Manual Phar and Cosumer Protection

Documents

Transcript of PCU Manual Phar and Cosumer Protection